Grünenthal is a global leader in pain management.

Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better, and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a world free of pain.

Our Vision: A World Free of Pain

Grünenthal Stories

Full Years Results 2023

Grünenthal 2023 full-year results

In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10 percent over prior year. The adjusted EBITDA was €427 million, a decrease of three percent vs. prior year due to increased investments in growth through Research & Development (R&D), acquisitions, and modernising production facilities. Grünenthal has more than tripled its adjusted EBITDA since 2017. Grünenthal’s R&D pipeline has progressed substantially with its Phase III development projects of RTX and Qutenza™.
... Read the 2023 full-year results press release

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to resiniferatoxin for pain associated with knee osteoarthritis (OA). The investigational, non-opioid medicine is currently in Phase III clinical development.

Knee OA affects more than 360 million people worldwide. Patients often experience severe pain, and many are impacted in their daily activities. If approved, resiniferatoxin could become a meaningful treatment option providing long-lasting pain relief and functional improvement of the affected joint.

Learn more about our asset and how it may address one of the most common and severe symptoms in knee OA

... Download PR FDA Breakthrough Therapy Designation for Grünenthal’s resiniferatoxin

Grünenthal announced that the company has enrolled the first patient in its global clinical Phase III programme for resiniferatoxin (RTX).

RTX is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist, with a well-validated mechanism of action. The discovery of TRPV1 was awarded the Nobel Prize of Physiology or Medicine in 2021. If approved, resiniferatoxin may provide patients with long-lasting pain relief with a favourable safety profile.

... Grünenthal starts global clinical Phase III programme for resiniferatoxin (RTX)
Job Portal - Tout Primary 1800x759px


Working at Grünenthal means experiencing the impact you can have on the results we achieve and the lives of the patients we serve.

Join forces.

Make an impact.

Innovate for a world free of pain.

... Visit our careers website